Hyperuricemia

Dietary Management Improves Disease-Specific, Metabolic Outcomes in Gout

Publish Date November 25, 2020

Nonpharmacologic therapy may improve management and the metabolic syndrome in patients with gout.

High Serum Urate Levels Associated With Poorer Health-Related Quality of Life Outcomes in Patients With Gout

Publish Date November 16, 2020

Study authors evaluated the association between serum urate levels and health-related quality of life in patients with gout.

Fatty Acid Synthesis Reduction Associated With Metabolic, Cardiovascular Comorbidities in Gout

Publish Date November 23, 2020

Researchers evaluated the association of metabolic and cardiovascular comorbidities in patients with gout receiving treat-to-target uric acid lowering therapy.

Gout Linked to Increased Length of Hospital Stay in Patients With Heart Failure Exacerbation

Publish Date November 19, 2020

Study authors examined the effect of gout diagnosis and flare on length of hospital stays in patients with heart failure exacerbation.

Dual-Energy Computed Tomography More Accurate Than Ultrasound for Gout Diagnosis

Publish Date November 18, 2020

Study authors evaluated the diagnostic accuracy of dual-energy computed tomography vs ultrasound, or their combination, for the diagnosis of gout.

Pegloticase and Methotrexate Combination Therapy Reduces Gout Flares

Publish Date November 17, 2020

Researchers prospectively examined the efficacy and safety of pegloticase in patients with uncontrolled gout who also received oral methotrexate.

No Increased Cardiovascular Risk Found With Febuxostat vs Allopurinol

Publish Date November 12, 2020

In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout.

Gout Risk Linked to Genetic Variants in Diuretic Users

Publish Date November 11, 2020

Single-nucleotide polymorphisms associated with serum urate can strongly influence gout susceptibility in the presence of other risk factors, according to investigators.

Comparative Performance of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes

Publish Date November 8, 2020

Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.

Allopurinol Dosage Reductions Found to Raise Gout Flare Risk

Publish Date November 6, 2020

In a study of patients hospitalized with acute gout flares and who had prescriptions for allopurinol, those who had their allopurinol dosages decreased had a higher rate of gout flares within 3 months of discharge.